SAB Biotherapeutics, a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, has signed multiple collaboration and option agreements with global biotherapeutics company, CSL Behring, it was reported yesterday.

The partnerships are intended to explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB's DiversitAb platform. SAB has developed a unique platform via advanced genetic engineering, to naturally and rapidly produce large amounts of human antibodies without using human donors.

The contract includes a research program that will investigate a potential new source for human immunoglobulin G (IgG). Human IgG is currently used for a number of immunological and neurological diseases. Both firms will share research program and related costs and plan to complete the initial phase in 2020. The partnership is likely to lead to subsequent development and commercialisation agreements.